Table of Contents
Journal of Radiotherapy
Volume 2014, Article ID 130652, 6 pages
http://dx.doi.org/10.1155/2014/130652
Research Article

Implant R100 Predicts Rectal Bleeding in Prostate Cancer Patients Treated with IG-IMRT to 45 Gy and Pd-103 Implant

1Department of Radiation Oncology, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212-9986, USA
2Department of Radiation Oncology, Temple University Hospital, 3401 N Broad Street, Philadelphia, PA 19140, USA

Received 26 September 2013; Revised 29 November 2013; Accepted 13 December 2013; Published 4 February 2014

Academic Editor: Andreas Meyer

Copyright © 2014 Matthew Packard et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Cancer Society, Cancer Facts and Figures 2010, American Cancer Society, Atlanta, Ga, USA, 2010.
  2. R. G. Stock, N. N. Stone, J. A. Cesaretti, and B. S. Rosenstein, “Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results,” International Journal of Radiation Oncology, Biology, Physics, vol. 64, no. 2, pp. 527–533, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. M. J. Zelefsky, Z. Fuks, M. Hunt et al., “High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients,” International Journal of Radiation Oncology, Biology, Physics, vol. 53, no. 5, pp. 1111–1116, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. O. Cahlon, M. J. Zelefsky, A. Shippy et al., “Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes,” International Journal of Radiation Oncology, Biology, Physics, vol. 71, no. 2, pp. 330–337, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. I. Latorzeff, J. Mazurier, C. Boutry, P. Dudouet, P. Richaud, and R. de Crevoisier, “Benefit of intensity modulated and image-guided radiotherapy in prostate cancer,” Cancer Radiothérapie, vol. 14, no. 6-7, pp. 479–487, 2010. View at Google Scholar · View at Scopus
  6. M. J. Zelefsky, M. Kollmeier, B. Cox et al., “Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer,” International Journal of Radiation Oncology, Biology, Physics, vol. 84, no. 1, pp. 125–129, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Valakh, A. Kirichenko, R. Miller, T. Sunder, L. Miller, and R. Fuhrer, “Combination of IG-IMRT and permanent source prostate brachytherapy in patients with organ-confined prostate cancer: GU and GI toxicity and effect on erectile function,” Brachytherapy, vol. 10, no. 3, pp. 195–200, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Zelefsky, Y. Yamada, G. N. Cohen et al., “Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications,” Radiotherapy and Oncology, vol. 84, no. 2, pp. 185–189, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. K. M. Snyder, R. G. Stock, S. M. Hong, Y. C. Lo, and N. N. Stone, “Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis,” International Journal of Radiation Oncology, Biology, Physics, vol. 50, no. 2, pp. 335–341, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Bittner, K. Wallner, G. Merrick, P. Orio, R. Nurani, and L. True, “The time gap between Pd-103 prostate brachytherapy and supplemental beam radiation does not impact on rectal morbidity or likelihood of cure,” American Journal of Clinical Oncology, vol. 31, no. 3, pp. 231–236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Sherertz, K. Wallner, G. Merrick et al., “Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer,” Brachytherapy, vol. 3, no. 3, pp. 130–135, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Shiraishi, A. Yorozu, T. Ohashi et al., “Dose constraint for minimizing grade 2 rectal bleeding following brachytherapy combined with external beam radiotherapy for localized prostate cancer: rectal dose-volume histogram analysis of 457 patients,” International Journal of Radiation Oncology, Biology, Physics, vol. 81, no. 3, pp. e127–e133, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Kalakota, E. Rakhno, C. A. Pelizzari, A. B. Jani, and S. L. Liauw, “Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis,” Brachytherapy, vol. 9, no. 2, pp. 131–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, March 2003, http://ctep.cancer.gov/.
  15. W. R. Lee, M. DeSilvio, C. Lawton et al., “A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019,” International Journal of Radiation Oncology, Biology, Physics, vol. 64, no. 3, pp. 804–809, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. W. R. Lee, K. Bae, C. Lawton et al., “Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019,” Cancer, vol. 109, no. 8, pp. 1506–1512, 2007. View at Publisher · View at Google Scholar · View at Scopus